Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD


November 23, 2021

Even though HER2 is emerging as a promising target for advanced NSCLC, its role has not yet been confirmed. Thus, ESMO recommends that patients with metastatic HER2-mutated NSCLC should be enrolled in a clinical trial. Recruiting trials of targeted therapy for HER2-mutated NSCLC include DESTINY-Lung02 and a phase 2 trial of ado-trastuzumab emtansine for patients with HER2 amplified or mutant cancers. Search for additional clinical trials here. ESMO guidelines can be accessed here.

Learn more about targeting HER2 in NSCLC.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.